Probiotics-addicted low-protein diet for microbiota modulation in patients with advanced chronic kidney disease (ProLowCKD): A protocol of placebo-controlled randomized trial
| Autor: | Deborah Carrera, Doriana Chiarinotti, Marco Pane, Roberta Rolla, Angela Amoruso, Mario Del Piano, Luca Mogna, Andreana De Mauri, Marco Bagnati |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Bifidobacterium longum medicine.medical_treatment Probiotic bacteria Population Medicine (miscellaneous) Gut microbiota Placebo Gastroenterology law.invention 03 medical and health sciences 0404 agricultural biotechnology Randomized controlled trial Low-protein diet law Internal medicine Chronic kidney disease medicine Microbial uremic toxins TX341-641 education Dialysis education.field_of_study 030109 nutrition & dietetics Nutrition and Dietetics biology business.industry Nutrition. Foods and food supply 04 agricultural and veterinary sciences medicine.disease biology.organism_classification 040401 food science Lactobacillus reuteri Low protein diet Intestinal dysbiosis business Food Science Kidney disease |
| Zdroj: | Journal of Functional Foods, Vol 74, Iss, Pp 104133-(2020) |
| ISSN: | 1756-4646 |
| Popis: | Microbiota is a term coined to describe the population of bacteria, viruses and fungi that inhabit in symbiosis within a living host. A connection between unbalanced microbiota and chronic kidney disease has been established. In these patients, high levels of urea reach the intestine promoting the overgrowth of bacterial species that are prone to generate uremic toxins. Due to the high morbidity and mortality of this condition, a large number of therapeutic approaches to reduce inflammation and microbial uremic toxins have been proposed, with controversial results. A low protein diet, with a protein intake of 0.6–0.8 g/kg of body weight, is a useful and historically pursued option with this regard. The aim of our study is to evaluate, among patients with advanced renal failure not on dialysis, the synergic beneficial effects of this diet and the selected probiotics Bifidobacterium longum (mix DLBL) and Lactobacillus reuteri LRE02 (DSM 23878). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect